Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.
At least one of the UK's biotech companies is home and dry. Much of the sector is paying a high price for failing to raise enough cash during the biotech boom, and remains stubbornly resistant to consolidation. (See "UK Biotech Learns the Hard Way," START-UP, March 2002 Also see "UK Biotech Learns the Hard Way" - Scrip, 1 March, 2002..)
Cancer company Antisoma PLC was no exception. To avoid dilution, it only raised top-up funding of £8.7 million ($13.7...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
